Biotechnology • Pharmaceuticals • Disruptive Innovation
Robert Nelsen is a co-founder and a Managing Director of ARCH Venture Partners. He joined ARCH at its founding and played a significant role in the early sourcing, financing and development of more than thirty companies, including thirteen which have reached valuations exceeding $1 billion. His seed and early-stage investments include Illumina (ILMN); Alnylam Pharmaceuticals (ALNY); Juno Therapeutics (JUNO); Agios Pharmaceuticals (AGIO); Sage Therapeutics (SAGE); Ikaria (acquired by Madison Dearborn); Kythera Biopharmaceuticals (KYTH), Aviron (AVIR, acquired by Medimmune-MEDI); Sapphire Energy; NetBot (acquired by Excite-ATHM); R2 Technology (acquired by Hologic-HOLX); XenoPort (XNPT); Caliper Life Sciences (CALP, acquired by PerkinElmer); Bluebird Bio (BLUE); Trubion Pharmaceuticals (TRBN, acquired by Emergent BioSolutions-EBS); Adolor (ADLR, acquired by Cubist-CBST); deCODE Genetics (acquired by Amgen-AMGN); Array BioPharma (ARRY); Nanosys; GenVec (GNVC); IDUN Pharmaceuticals (acquired by Pfizer-PFE); Genomica (GNOM, acquired by Exelixis-EXEL); Classmates.com (acquired by United Online-UNTD); Nura (acquired by Omeros-OMER); Receptos (RCPT); Aledade; Kilimanjaro Energy; Hua Medicine; VLST; Ensemble Therapeutics; Accelerator; Theraclone Sciences; Fate Therapeutics (FATE); NextCODE Health (acquired by WuXi Genomics); Bellerophon Therapeutics; Syros Pharmaceuticals, and Everyday Learning Corporation (acquired by Tribune Corp.-TRIB.)
Mr. Nelsen is a director of Agios Pharmaceuticals, Juno Therapeutics, Sapphire Energy, Sage Therapeutics, Ensemble Therapeutics, Syros Pharmaceuticals, Aledade, and serves as Chairman of Hua Medicine. He previously served as a Trustee of the Fred Hutchinson Cancer Research Institute, the Institute for Systems Biology, and as a director of the National Venture Capital Association. Mr. Nelsen holds an M.B.A. from the University of Chicago and a B.S. from the University of Puget Sound with majors in Economics and Biology.